An FT investigation has found a thriving market for stem cell therapies in the US promising longer, healthier lives. Experts say such claims are dangerous
Related stories
Google value plunges by $500bn as AI fears rattle Wall Street
What killed Weil Gotshal?
Uproar in Alaska sparks Democratic fears for Senate majority
A Starbucks turnaround is brewing — but perhaps not quickly enough
Sandisk sees revenue nearly quintuple — and its stock is heading higher
The stock market’s best forecasting tool says returns over the next 10 years will be dismal